Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endogenous adenosine is an antiarrhythmic agent

J B Conti1, L Belardinelli, D B Utterback

  • 1Department of Medicine, University of Florida, Gainesville 32610.

Circulation
|March 15, 1995
PubMed
Summary

Dipyridamole infusion increases coronary sinus adenosine levels, prolonging AV nodal refractory periods and potentially terminating supraventricular tachycardia (SVT). This suggests adenosine acts as an endogenous antiarrhythmic agent.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The novel CaMKII inhibitor GS-680 reduces diastolic SR Ca leak and prevents CaMKII-dependent pro-arrhythmic activity.

Journal of molecular and cellular cardiology·2018
Same author

Using GIS Mapping to Target Public Health Interventions: Examining Birth Outcomes Across GIS Techniques.

Journal of community health·2016
Same author

Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.

Diabetes, obesity & metabolism·2016
Same author

Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action.

British journal of pharmacology·2010
Same author

Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats.

Diabetes, obesity & metabolism·2008
Same author

Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium.

British journal of pharmacology·2007

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pharmacology

Background:

  • Adenosine is known to terminate supraventricular tachycardias (SVT) involving the AV node.
  • Dipyridamole enhances myocardial adenosine levels.
  • The study investigated if dipyridamole-induced adenosine increases are sufficient to alter electrophysiological parameters and terminate SVT in humans.

Purpose of the Study:

  • To determine if intravenous dipyridamole increases coronary sinus plasma adenosine concentrations ([Ado]cs) in humans.
  • To assess the impact of elevated [Ado]cs on electrophysiological parameters, specifically AV nodal function.
  • To evaluate the potential of dipyridamole to terminate SVT.

Main Methods:

  • Coronary sinus blood sampling in patients undergoing electrophysiological studies.

Related Experiment Videos

  • Measurement of [Ado]cs before and after dipyridamole infusion (loading dose and maintenance infusion).
  • Assessment of atrial and AV nodal refractory periods and conduction characteristics, including Wenckebach cycle length and AH interval.

    • Main Results:

    • Dipyridamole administration significantly increased [Ado]cs.
    • AV nodal functional refractory period and Wenckebach cycle length were prolonged.
    • During SVT, dipyridamole increased AH interval and tachycardia cycle length, leading to termination in 4 out of 10 patients.

    Conclusions:

    • Dipyridamole elevates coronary sinus adenosine levels, prolonging AV nodal refractoriness.
    • Increased adenosine levels correlate with prolonged AH interval and tachycardia cycle length during SVT.
    • These findings support adenosine's role as an endogenous antiarrhythmic metabolite.